NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors

NCT04250597
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with a history of CNS metastases, unless previously treated and stable for at least 4 weeks in the absence of steroids; Patients with meningeal carcinomatosis
https://ClinicalTrials.gov/show/NCT04250597

Comments are closed.

Up ↑